TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27486926

Group type: EXPERIMENTAL
Intervention: Directive Control (Food restriction)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Directive Control (Pressure-to-eat)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Non-Directive Control (Obesogenic home food environment)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Non-Directive Control (Parental role modeling of healthful eating)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Directive Control
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Non-Directive Control
Number of subjects: 160
Study: 24748301

Group type: EXPERIMENTAL
Intervention: Glass fiber-reinforced post (FRP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Stainless steel parapost (PP)
Number of subjects: 40
Study: 21248612

Group type: EXPERIMENTAL
Intervention: Tranexamic acid modified‐immediate‐release (MIR) 1.3 g (2 650‐mg tablets)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Tranexamic acid delayed‐release (DR) 1.3 g (2 650‐mg tablets)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Tranexamic acid MIR 1.3 g dosed every 8 hours for 5 days
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Tranexamic acid DR 1.3 g
Number of subjects: 72
Study: 20337841

Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic gastrostomy
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Combined modality treatment (Induction Chemotherapy and Chemoradiation)
Number of subjects: 196
Study: 18692658

Group type: EXPERIMENTAL
Intervention: Medtronic Advantage Supra
Number of subjects: 80

Group type: COMPARATOR
Intervention: St Jude Medical Regent
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 15188756

Group type: EXPERIMENTAL
Intervention: Trimetazidine (60 mg/kg)
Number of subjects: 0
Study: 11719116

Group type: EXPERIMENTAL
Intervention: Impedance‐compensated biphasic truncated exponential (ICBTE) AED
Number of subjects: 338

Group type: COMPARATOR
Intervention: Monophasic truncated exponential (MTE) AED
Number of subjects: 338

Group type: COMPARATOR
Intervention: Monophasic damped sine (MDS) AED
Number of subjects: 338

Group type: COMPARATOR
Intervention: All waveforms (ICBTE, MTE, MDS)
Number of subjects: 338
Study: 8985227

Group type: EXPERIMENTAL
Intervention: Desferrioxamine plus quinine
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo plus quinine
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Desferrioxamine
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 39
Study: 7963426

Group type: EXPERIMENTAL
Intervention: Propranolol plus sclerotherapy
Number of subjects: 73

Group type: COMPARATOR
Intervention: Sclerotherapy alone
Number of subjects: 73
Study: 3630808

Group type: EXPERIMENTAL
Intervention: Medically-based control program with advice to quit from physicians and nurses
Number of subjects: 250
Study: 30415407

Group type: EXPERIMENTAL
Intervention: Esomeprazole (20 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vonoprazan (20 mg/day)
Number of subjects: 60
Study: 30125336

Group type: EXPERIMENTAL
Intervention: Intrauterine contraception
Number of subjects: 748

Group type: COMPARATOR
Intervention: Hormonal contraceptive methods
Number of subjects: 748

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 748
Study: 26234336

Group type: EXPERIMENTAL
Intervention: Memantine (20 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 24299914

Group type: EXPERIMENTAL
Intervention: Detailed training documentation on standardized BP measurement (group I: 14 doctors)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Information about high BP (group II: 12 doctors)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Baseline measurements by PCPs
Number of subjects: 257

Group type: COMPARATOR
Intervention: Misdiagnosis rates
Number of subjects: 257
Study: 22316839

Group type: EXPERIMENTAL
Intervention: School based exercise program (twice a week for six weeks, 50 minutes per session)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 58
Study: 20430576

Group type: EXPERIMENTAL
Intervention: RCTs registered in a trial registry
Number of subjects: 148

Group type: COMPARATOR
Intervention: RCTs not registered in a trial registry
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Overall adherence to CONSORT items
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: All RCTs
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Registered RCTs
Number of subjects: 148
Study: 17692991

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (40 kDa) plus ribavirin for 72 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Peginterferon alfa-2a (40 kDa) plus ribavirin for 48 weeks
Number of subjects: 0
Study: 15882220

Group type: EXPERIMENTAL
Intervention: 1.5% dexibuprofen mouth rinse
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 11277962

Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg once daily for 6 weeks
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 9252849

Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxyvitamin D (0.5 microgram twice a day for 5 days) + calcium carbonate (1,500 mg/day) + carbocalcitonin (40 UMRC intramuscularly three times weekly)
Number of subjects: 59

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 59
Study: 8503418

Group type: EXPERIMENTAL
Intervention: Intraperitoneal recombinant human erythropoietin (Epo) at 99.1 U/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human erythropoietin (Epo)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant human erythropoietin (Epo)
Number of subjects: 8
Study: 3606167

Group type: EXPERIMENTAL
Intervention: Tap water iontophoresis
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (untreated hand)
Number of subjects: 18
Study: 29546554

Group type: EXPERIMENTAL
Intervention: Primary titanium cranioplasty
Number of subjects: 64

Group type: COMPARATOR
Intervention: Autologous bone graft
Number of subjects: 64
Study: 28490515

Group type: EXPERIMENTAL
Intervention: Iron (60 mg)
Number of subjects: 809

Group type: EXPERIMENTAL
Intervention: Multiple Micronutrients (14 other micronutrients)
Number of subjects: 809

Group type: EXPERIMENTAL
Intervention: Iron plus Multiple Micronutrients
Number of subjects: 809

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 809
Study: 26058479

Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning (IPC)
Number of subjects: 15

Group type: COMPARATOR
Intervention: SHAM
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 15
Study: 23416018

Group type: EXPERIMENTAL
Intervention: Baseline LAmin volume
Number of subjects: 1159

Group type: EXPERIMENTAL
Intervention: LAmin volume added to a model with classic risk factors for AF
Number of subjects: 1159

Group type: EXPERIMENTAL
Intervention: LAmin volume compared to other LA measurements
Number of subjects: 1159

Group type: EXPERIMENTAL
Intervention: Cox multivariable analysis
Number of subjects: 1159
Study: 21700892

Group type: EXPERIMENTAL
Intervention: Ozone (O₃) exposure (220 ppb)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Filtered air (FA)
Number of subjects: 138
Study: 17509587

Group type: EXPERIMENTAL
Intervention: Transdermal E(2) therapy (100 microg/d)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control group (regularly menstruating women)
Number of subjects: 137
Study: 16865142

Group type: EXPERIMENTAL
Intervention: 20% citric acid solution and photo‐activated disinfection
Number of subjects: 64

Group type: COMPARATOR
Intervention: 20% citric acid and 2.25% sodium hypochlorite solutions
Number of subjects: 64
Study: 12789897

Group type: EXPERIMENTAL
Intervention: Community Treatment Program
Number of subjects: 0
Study: 10828648

Group type: EXPERIMENTAL
Intervention: Cladribine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 9348567

Group type: EXPERIMENTAL
Intervention: Oral UFT plus leucovorin
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-FU plus leucovorin
Number of subjects: 0
Study: 7934682

Group type: EXPERIMENTAL
Intervention: Atropine 15 micrograms/kg and neostigmine 40 micrograms/kg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Atropine 8 micrograms/kg and edrophonium 0.75 mg/kg
Number of subjects: 100
Study: 30667205

Group type: EXPERIMENTAL
Intervention: Chronic exercise (endurance, resistance, and flexibility training for six months)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chronic exercise
Number of subjects: 30
Study: 29216361

Group type: EXPERIMENTAL
Intervention: OBE2109 100 mg
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: OBE2109 200 mg
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: OBE2109 100 mg/1.0 mg/0.5 mg (add-back therapy)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: OBE2109 200 mg (with E2/NETA)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: OBE2109/E2/NETA (100/0.5/0.1 or 100/1.0/0.5)
Number of subjects: 76
Study: 27344235

Group type: EXPERIMENTAL
Intervention: AL-Scan (Nidek CO, Aichi, Japan)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Lenstar LS 900 (Haag‐Streit AG, Köniz, Switzerland)
Number of subjects: 65

Group type: COMPARATOR
Intervention: AL-Scan and Lenstar comparison
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: AL measurements
Number of subjects: 65
Study: 25102719

Group type: EXPERIMENTAL
Intervention: Oil-free pumice
Number of subjects: 46

Group type: COMPARATOR
Intervention: Oil-containing Prophy Paste
Number of subjects: 46
Study: 23290909

Group type: COMPARATOR
Intervention: TACE
Number of subjects: 97

Group type: COMPARATOR
Intervention: PVC per-DDS TACE
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: PVC per-DDS
Number of subjects: 97
Study: 20216564

Group type: EXPERIMENTAL
Intervention: Probiotic yogurt-based drink with Bifidobacterium animalis ssp. lactis (B. lactis) BB-12
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo yogurt-based drink without Bifidobacterium animalis ssp. lactis (B. lactis) BB-12
Number of subjects: 182
Study: 18301060

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 1776

Group type: EXPERIMENTAL
Intervention: Viral suppression (by > 1.0 log10 copies/ml or to < 400 copies/ml)
Number of subjects: 1776

Group type: COMPARATOR
Intervention: Higher CD4 cell counts
Number of subjects: 1776
Study: 16463698

Group type: EXPERIMENTAL
Intervention: CHC patients
Number of subjects: 29

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 29
Study: 12185552

Group type: EXPERIMENTAL
Intervention: Sumatriptan 3 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sumatriptan 6 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10360912

Group type: EXPERIMENTAL
Intervention: Urinary LH monitoring timed IUI
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: hCG-timed IUI
Number of subjects: 141
Study: 7815583

Group type: EXPERIMENTAL
Intervention: Peak velocity flow measurement using color duplex Doppler ultrasound
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Abnormal peak velocity flow
Number of subjects: 27
Study: 2007318

Group type: EXPERIMENTAL
Intervention: Intravenous furosemide
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral furosemide
Number of subjects: 12
Study: 7133973

Group type: EXPERIMENTAL
Intervention: pirprofen (600 mg/day)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: indomethacin (75 mg/day)
Number of subjects: 137

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 137
Study: 31652261

Group type: EXPERIMENTAL
Intervention: Synthetic pheromone + insecticide
Number of subjects: 1454

Group type: EXPERIMENTAL
Intervention: Insecticide-impregnated collars
Number of subjects: 1454

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 1454
Study: 29017796

Group type: EXPERIMENTAL
Intervention: Collagen tripeptide (CTP) 3.9g daily for 12 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Normal collagen peptides (CP)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Collagen tripeptide (CTP)
Number of subjects: 17
Study: 26434023

Group type: EXPERIMENTAL
Intervention: Explanation of correct technique of foot placement in barefoot running and running in minimalistic shoes (groups 2 and 4)
Number of subjects: 39

Group type: COMPARATOR
Intervention: No explanation of correct technique (groups 1 and 3)
Number of subjects: 39
Study: 22782256

Group type: EXPERIMENTAL
Intervention: Self-adhesive resin cement (SARC) iCem (Heraeus Kulzer)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Resin-modified glass ionomer cement (RMGIC) GC Fuji PLUS
Number of subjects: 88
Study: 21844964

Group type: EXPERIMENTAL
Intervention: CQS-01 device
Number of subjects: 86

Group type: COMPARATOR
Intervention: EMS-III device
Number of subjects: 86
Study: 19531413

Group type: EXPERIMENTAL
Intervention: Gap arthroplasty
Number of subjects: 16

Group type: COMPARATOR
Intervention: Interpositional arthroplasty with temporalis myofacial flap
Number of subjects: 16
Study: 17341247

Group type: EXPERIMENTAL
Intervention: 0.25 mg/d of micronized 17beta-estradiol (estrogen therapy, n=32)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo (n=25)
Number of subjects: 57
Study: 15226327

Group type: EXPERIMENTAL
Intervention: Docetaxel plus cisplatin (DC)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Docetaxel (D)
Number of subjects: 319
Study: 11153533

Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg daily for 2 weeks)
Number of subjects: 8
Study: 9556465

Group type: EXPERIMENTAL
Intervention: Noninvasive pressure support ventilation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Invasive pressure support ventilation
Number of subjects: 50
Study: 7831450

Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3342289

Group type: EXPERIMENTAL
Intervention: New tablet formulation of carbocysteine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Syrup containing carbocysteine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Capsules containing carbocysteine
Number of subjects: 0
Study: 30048223

Group type: EXPERIMENTAL
Intervention: 50 mL irrigation volume
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 200 mL irrigation volume
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison between 50 mL and 200 mL irrigation volumes
Number of subjects: 30
Study: 29956087

Group type: EXPERIMENTAL
Intervention: Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Abacavir, Dolutegravir, and Lamivudine (ABC/DTG/3TC)
Number of subjects: 0
Study: 28114399

Group type: EXPERIMENTAL
Intervention: Body Monochord
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Relaxation music
Number of subjects: 42
Study: 26673534

Group type: EXPERIMENTAL
Intervention: 3D imaging in large training box
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 3D imaging in small training box
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 3D imaging in both boxes
Number of subjects: 24

Group type: COMPARATOR
Intervention: 2D imaging in large training box
Number of subjects: 24

Group type: COMPARATOR
Intervention: 2D imaging in small training box
Number of subjects: 24
Study: 23371792

Group type: EXPERIMENTAL
Intervention: Reminding during the presentation of later instances
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (no reminding)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reminding
Number of subjects: 0
Study: 21683750

Group type: EXPERIMENTAL
Intervention: EmulGold(®) (EG) at doses of 40 g
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PreVitae(®) (PV) at doses of 40 g
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EmulGold(®) (EG) at doses of 10 or 20 g
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EmulGold(®) (EG) at doses of 5 and 10 g
Number of subjects: 0

Group type: COMPARATOR
Intervention: All doses of both gums compared to negative control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative control (250 ml of water)
Number of subjects: 0
Study: 18459351

Group type: EXPERIMENTAL
Intervention: Oddball face (15% of trials)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel probe stimuli (15% of trials)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Frequent face (70% of trials)
Number of subjects: 0
Study: 16550734

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily + clarithromycin 500 mg b.i.d. + amoxicillin 1 g b.i.d. for 7 days
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg b.i.d. + clarithromycin 500 mg b.i.d. + amoxicillin 1 g b.i.d. for 7 days
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily with clarithromycin 500 mg b.i.d. for 1 week
Number of subjects: 26

Group type: COMPARATOR
Intervention: Esomeprazole 40 mg once daily
Number of subjects: 26

Group type: COMPARATOR
Intervention: Esomeprazole 20 mg b.i.d.
Number of subjects: 26
Study: 12910115

Group type: EXPERIMENTAL
Intervention: Early tracheostomy (before the 4th day of MV)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Translaryngeal intubation (control)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Early tracheostomy
Number of subjects: 468
Study: 11145281

Group type: EXPERIMENTAL
Intervention: PPI treatment (30 mg lansoprazole/day for 8 weeks followed by 15 or 30 mg lansoprazole or 20 mg omeprazole/day for 12 months)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: PPI treatment
Number of subjects: 295
Study: 8794399

Group type: EXPERIMENTAL
Intervention: Asthma education and management service
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline audit
Number of subjects: 0
Study: 2000109

Group type: EXPERIMENTAL
Intervention: Surfactant as prophylaxis (90 mg intratracheal dose at delivery)
Number of subjects: 479

Group type: COMPARATOR
Intervention: Surfactant as rescue therapy (90 mg intratracheal dose several hours after delivery if criteria met)
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Surfactant as prophylaxis (for infants ≤ 26 weeks' gestation)
Number of subjects: 479

Group type: COMPARATOR
Intervention: Surfactant as rescue therapy (for infants ≤ 26 weeks' gestation)
Number of subjects: 479
Study: 6519358

Group type: EXPERIMENTAL
Intervention: Propanolol
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 31663962

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) protocol
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 160
Study: 29728148

Group type: EXPERIMENTAL
Intervention: GTO group (Veterans with access to MISSION-Vet)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Non-GTO group (Veterans without access to MISSION-Vet)
Number of subjects: 168
Study: 28031612

Group type: EXPERIMENTAL
Intervention: Prelecture assignment (PLA) provided before the lecture
Number of subjects: 150

Group type: COMPARATOR
Intervention: Direct lecture attendance without PLA
Number of subjects: 150
Study: 24401940

Group type: EXPERIMENTAL
Intervention: Maxalt (10‐mg rizatriptan)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo labeled as placebo
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Placebo labeled as Maxalt or placebo
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Placebo labeled as Maxalt
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Open‐label placebo
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo under each information condition
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Maxalt under each information condition
Number of subjects: 66
Study: 23608089

Group type: EXPERIMENTAL
Intervention: Home-based voluntary HIV counselling and testing (HB-VCT) offered by local lay counsellors.
Number of subjects: 1694

Group type: EXPERIMENTAL
Intervention: Home-based voluntary HIV counselling and testing (HB-VCT)
Number of subjects: 1694

Group type: COMPARATOR
Intervention: Standard HIV testing services (Control)
Number of subjects: 1694

Group type: COMPARATOR
Intervention: Home-based voluntary HIV counselling and testing (HB-VCT) and Standard HIV testing services (Control)
Number of subjects: 1694
Study: 20443650

Group type: EXPERIMENTAL
Intervention: Olopatadine 5 mg
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Olopatadine 2.5 mg
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 17588581

Group type: EXPERIMENTAL
Intervention: High doses of Candesartan (32 mg)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Conventional doses of Candesartan (16 mg)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (other antihypertensive treatment)
Number of subjects: 69
Study: 16805936

Group type: EXPERIMENTAL
Intervention: Propofol 2 mg kg‐1 h‐1
Number of subjects: 24

Group type: COMPARATOR
Intervention: Dexmedetomidine 0.2 microg kg‐1 h‐1
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study: 12499328

Group type: EXPERIMENTAL
Intervention: Alcohol meal (23% of energy)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Protein meal (32% of energy)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Carbohydrate meal (65% of energy)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Fat meal (65% of energy)
Number of subjects: 19
Study: 10690672

Group type: EXPERIMENTAL
Intervention: Diclofenac 50 mg rectally 3 times during the first 24 hours postoperatively
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo 3 times during the first 24 hours postoperatively
Number of subjects: 50
Study: 9374256

Group type: EXPERIMENTAL
Intervention: Heparin-coated IOLs
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard IOLs
Number of subjects: 19
Study: 8263310

Group type: EXPERIMENTAL
Intervention: d-fenfluramine and d-amphetamine combination
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: d-fenfluramine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: l-fenfluramine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: racemic fenfluramine
Number of subjects: 12
Study: 3834831

Group type: EXPERIMENTAL
Intervention: Rimantadine hydrochloride (200 mg single dose)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride (200 mg single dose)
Number of subjects: 12